Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nurix TherapeuticsNRIX +0.36%61 PB Ratio is 6.49 as of Aug. 07, 2026, which is 128% above its 10-year median of 2.85. GuruFocus rates NRIX with a GF Score™ of 61/100 and a GF Value™ of $6.41 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,228 Biotechnology companies, Nurix Therapeutics ranks worse than 76.95% on this metric.
Nurix Therapeutics Inc stock PB Ratio (=6.49) is close to 5-year high of 6.49.
The historical rank and industry rank for Nurix Therapeutics's PB Ratio or its related term are showing as below:
NRIX'
s PB Ratio Range Over the Past 10 Years
Min: 0.91 Med: 2.85 Max: 8.78
Current: 6.49
During the past 8 years, Nurix Therapeutics's highest PB Ratio was 8.78. The lowest was 0.91. And the median was 2.85.
NRIX's PB Ratio is ranked worse than 76.95% of 1228
companies
in the Biotechnology industry
Industry Median: 2.905
vs NRIX: 6.49
During the past 12 months, Nurix Therapeutics's average Book Value Per Share Growth Rate was -33.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -6.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -6.80% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Nurix Therapeutics was -3.20% per year. The lowest was -18.00% per year. And the median was -6.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Nurix Therapeutics PB Ratio Related Terms
Nurix Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Nurix Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Nurix Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nurix Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nurix Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Nurix Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Nurix Therapeutics (NRIX) has a PB Ratio of 6.49 as of Aug. 07, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Nurix Therapeutics and its competitors. This is 128% above median its historical median of 2.85. Over the past decade, Nurix Therapeutics' PB Ratio has ranged from 0.91 to 8.78. According to the industry distribution chart, Nurix Therapeutics ranks #945 out of 1228 companies in the Biotechnology industry, placing it in the top 77%.
Is Nurix Therapeutics' PB Ratio too high?
Nurix Therapeutics' current PB Ratio of 6.49 is 128% above median its 10-year median of 2.85. Over the past 10 years, this metric has ranged from a low of 0.91 to a high of 8.78. The Biotechnology industry median PB Ratio is 2.91. Nurix Therapeutics' value of 6.49 is 123.4% above this industry median. Based on the distribution chart, Nurix Therapeutics ranks #945 out of 1228 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Nurix Therapeutics has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nurix Therapeutics' PB Ratio compare to PHVS and NKTR?
According to the Biotechnology industry distribution chart, Nurix Therapeutics ranks #945 out of 1228 companies for PB Ratio. This places Nurix Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.91. Nurix Therapeutics' value of 6.49 is 123.4% above this benchmark. Historically, Nurix Therapeutics' own PB Ratio has ranged from 0.91 to 8.78 over the past decade. While the company's 10-year median is 2.85 vs. the industry median of 2.91, Nurix Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.91, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nurix Therapeutics's current PB Ratio of 6.49 is 123.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Nurix Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nurix Therapeutics's current PB Ratio is 6.49, which is 128% above median its own 10-year median of 2.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nurix Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nurix Therapeutics (NRIX) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.41, compared to a current price of $25.22 — trading 293.4% above its estimated fair value. The current PB Ratio is 6.49, which is 128% above median its 10-year median of 2.85 and 123.4% above the Biotechnology industry median of 2.91. Nurix Therapeutics' overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Nurix Therapeutics (NRIX), the current PB Ratio is 6.49 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nurix Therapeutics (NRIX) Overvalued in 2026?
Based on GuruFocus' analysis, Nurix Therapeutics stock appears to be overvalued.
The current stock price of $25.22 is trading 293.4% above its estimated GF Value™ of $6.41.
GuruFocus considers Nurix Therapeutics to be Significantly Overvalued.
Key valuation signals for NRIX:
PB Ratio: 6.49 (128% above median its 10-year median of 2.85)
GF Value™: $6.41 vs. price of $25.22 (293.4% above fair value)
Industry Position: 123.4% above the Biotechnology median (#945 of 1228)
No single metric tells the full story. See the NRIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
61GF Score
Get the complete analysis for NRIX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NRIX has been successfully added to your 
